Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia

Tissue Antigens

Volumn 80, Issue 2, 2012, Pages 136-142

  Zakharyan, R ^a,b   Petrek, M ^b   Arakelyan, A ^a   Mrazek, F ^b   Atshemyan, S ^a   Boyajyan, A ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY   (Armenia)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Association; Blood levels; Enzyme linked immunosorbent assay; Interleukin 6; Polymerase chain reaction with sequence specific primers; Rs1800795; Schizophrenia

Indexed keywords

INTERLEUKIN 6;

ADULT; ALLELE; ARMENIA; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA;

ADULT; ALLELES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS; SCHIZOPHRENIA;

EID: 84864334611     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2012.01886.x     Document Type: Article

References (53)

1. van Os J, Rutten BP, Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull 2008: 34: 1066-82.
2. Suvisaari J. Risk factors of schizophrenia. Duodecim 2010: 126: 869-76.
3. Brown AS. The environment and susceptibility to schizophrenia. Prog Neurobiol 2011: 93: 23-58.
4. Müller N, Riedel M, Gruber R, Ackenheil M, Schwarz MJ. The immune system and schizophrenia. An integrative view. Ann N Y Acad Sci 2000: 917: 456-67.
5. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007: 7: 46.
6. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008: 63: 801-8.
7. Watanabe Y, Someya T, Nawa H. Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models. Psychiatry Clin Neurosci 2010: 64: 217-30.
8. Alkelai A, Lupoli S, Greenbaum L et al. Identification of new schizophrenia susceptibility loci in an ethnically homogeneous, family-based, Arab-Israeli sample. FASEB J 2011: 25: 4011-23.
9. Brenneman DE, Schultzberg M, Bartfai T, Gozes I. Cytokine regulation of neuronal survival. J Neurochem 1992: 58: 454-60.
10. Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006: 2: 619-26.
11. Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 2002: 57: 247-58.
12. Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Cytokine changes and tryptophan metabolites in medication-naÏve and medication-free schizophrenic patients. Neuropsychobiology 2009: 59: 123-9.
13. Löffler S, Klimke A, Kronenwett R, Kobbe G, Haas R, Fehsel K. Clozapine mobilizes CD34+ hematopoietic stem and progenitor cells and increases plasma concentration of interleukin 6 in patients with schizophrenia. J Clin Psychopharmacol 2010: 30: 591-5.
14. Lin CC, Chang CM, Chang PY, Huang TL. Increased interleukin-6 level in taiwanese schizophrenic patients. Chang Gung Med J 2011: 34: 375-81.
15. Igue R, Potvin S, Bah R et al. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 2011: 35: 1695-8.
16. Paul-Samojedny M, Kowalczyk M, Suchanek R et al. Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia: a case-control study. J Mol Neurosci 2010: 42: 112-9.
17. Zhong H, Peng L, Zhu Y, Dang J, Huo Z. Association of the polymorphisms in the promoter region of tumor necrosis factor alpha and interleukin 6 genes with schizophrenia. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2011: 28: 427-31.
18. Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998: 102: 1369-76.
19. Wypasek E, Undas A, Sniezek-Maciejewska M et al. The increased plasma C-reactive protein and interleukin-6 levels in patients undergoing coronary artery bypass grafting surgery are associated with the interleukin-6-174G > C gene polymorphism. Ann Clin Biochem 2010: 47: 343-9.
20. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Non-patient Edition (SCID-I/NP).New York:State Psychiatric Institute: Biometrics Research, 2001.
21. Sambrook J, Russell DW. Molecular Cloning: a Laboratory Manual, 3rd edn. New York:Cold Spring Harbor Laboratory Press, 2001.
22. Bunce M, O'Neil CM, Barnado MC et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB3, DRB4, DRB5&DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995: 6: 355-67.
23. Lalouel JM, Rohrwasser A. Power and replication in case-control studies. Am J Hypertens 2002: 15: 201-5.
24. International HapMap Consortium. The International HapMap Project. Nature 2003: 426: 789-96.
25. Mirowska-Guzel D, Gromadzka G, Mach A, Czlonkowski A, Czlonkowska A. Association of IL1A, IL1B, ILRN, IL6, IL10 and TNF-α polymorphisms with risk and clinical course of multiple sclerosis in a Polish population. J Neuroimmunol 2011: 236: 87-92.
26. Soroka NE, Morozova SA, Ilinsky VV, Trofimov DY, Rebrikov DV. Association between alleles of cytokine genes with rheumatoid arthritis in Russian population. J Clin Cell Immunol 2010: 1: 102.
27. Moscovis SM, Gordon AE, Al Madani OM et al. IL6 G-174C associated with sudden infant death syndrome in a Caucasian Australian cohort. Hum Immunol 2006: 67: 819-25.
28. Opdal SH, Rognum TO. The IL6 -174G/C polymorphism and sudden infant death syndrome. Hum Immunol 2007: 68: 541-3.
29. Poli F, Nocco A, Berra S et al. Allele frequencies of polymorphisms of TNFA, IL-6, IL-10 and IFNG in an Italian Caucasian population. Eur J Immunogenet 2002: 29: 237-40.
30. Schotte H, Schlüter B, Rust S, Assmann G, Domschke W, Gaubitz M. Interleukin-6 promoter polymorphism -174 G/C in Caucasian German patients with systemic lupus erythematosus. Rheumatology (Oxford) 2001: 40: 393-400.
31. Ray A, LaForge KS, Sehgal PB. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol 1990: 10: 5736-46.
32. Liu Y, Bernard HU, Apt D. NFI-B3, a novel transcriptional repressor of the nuclear factor I family, is generated by alternative RNA processing. J Biol Chem 1997: 272: 10739-45.
33. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000: 275: 18138.
34. Rein TR, Forster A, Krause A, Winnacker EL, Zorbas H. Organization of the α-globin promoter and possible role of nuclear factor I in an α-globin inducible and a noninducible cell line. J Biol Chem 1995: 270: 19643.
35. Cole SW, Arevalo JM, Manu K et al. Antagonistic pleiotropy at the human IL6 promoter confers genetic resilience to the pro-inflammatory effects of adverse social conditions in adolescence. Dev Psychol 2011: 47: 1173-80.
36. Pereira DS, Garcia DM, Narciso FM et al. Effects of 174 G/C polymorphism in the promoter region of the interleukin-6 gene on plasma IL-6 levels and muscle strength in elderly women. Braz J Med Biol Res 2011: 44: 123-9.
37. Giannitrapani L, Soresi M, Giacalone A et al. IL-6 -174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. OMICS 2011: 15: 183-6.
38. Hulkkonen J, Pertovaara M, Antonen J, Pasternack A, Hurme M. Elevated interleukin-6 plasma levels are regulated by the promoter region polymorphism of the IL6 gene in primary Sjögren's syndrome and correlate with the clinical manifestations of the disease. Rheumatology (Oxford) 2001: 40: 656-61.
39. Vallance K, Yang J, Li J, Crabtree VM, Hinds PS, Mandrell BN. Disturbed sleep in pediatric patients with leukemia: the potential role of interleukin-6 (-174G/C) and tumor necrosis factor (-308G/A) polymorphism. Oncol Nurs Forum 2011: 38: E365-72.
40. Clerici M, Arosio B, Mundo E et al. Cytokine polymorphisms in the pathophysiology of mood disorders. CNS Spectr 2009: 14: 419-25.
41. Paradowski B, Celczyńska D, Dobosz T, Noga L. Polymorphism 174 G/C of interleukin 6 gene in Alzheimer's disease - preliminary report. Neurol Neurochir Pol 2008: 42: 312-5.
42. Capurso C, Solfrizzi V, Colacicco AM et al. Interleukin 6-174 G/C promoter and variable number of tandem repeats (VNTR) gene polymorphisms in sporadic Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2010: 34: 177-82.
43. Klimkowicz-Mrowiec A, Wolkow P, Spisak K et al. Interleukin-6 gene (-174C/G) and apolipoprotein E gene polymorphisms and the risk of Alzheimer disease in a Polish population. Neurol Neurochir Pol 2010: 44: 537-41.
44. Han XM, Wang CH, Sima X, Liu SY. Interleukin-6 -174G/C polymorphism and the risk of Alzheimer's disease in Caucasians: a meta-analysis. Neurosci Lett 2011: 504: 4-8.
45. Vural P, Deǧirmencioǧlu S, Parildar-Karpuzoǧlu H et al. The combinations of TNFalpha-308 and IL-6 -174 or IL-10 -1082 genes polymorphisms suggest an association with susceptibility to sporadic late-onset Alzheimer's disease. Acta Neurol Scand 2009: 120: 396-401.
46. Hong CJ, Yu YW, Chen TJ, Tsai SJ. Interleukin-6 genetic polymorphism and Chinese major depression. Neuropsychobiology 2005: 52: 202-5.
47. Misener VL, Gomez L, Wigg KG et al. International consortium for childhood-onset mood disorders. Cytokine genes TNF, IL1A, IL1B, IL6, IL1RN and IL10, and childhood-onset mood disorders. Neuropsychobiology 2008: 58: 71-80.
48. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011: 70: 663-71.
49. Hope S, Melle I, Aukrust P et al. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord 2009: 11: 726-34.
50. Hope S, Dieset I, Agartz I et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res 2011: 45: 1608-16.
51. Singh B, Bera NK, Nayak CR, Chaudhuri TK. Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients. Cytokine 2009: 47: 1-5.
52. Sanderson SC, Kumari M, Brunner EJ et al. Association between IL6 gene variants -174G > C and -572G > C and serum IL-6 levels: interactions with social position in the Whitehall II cohort. Atherosclerosis 2009: 204: 459-64.
53. Yang X, Jansson PA, Pellmé F, Laakso M, Smith U. Effect of the interleukin-6 (-174) g/c promoter polymorphism on adiponectin and insulin sensitivity. Obes Res 2005: 13: 813-7.